Morning

Start Strong.

Leveraging proprietary technologies to address significant unmet medical needs.

DELEXIS® - Proprietary Drug Delivery Platform

Highland’s wholly owned subsidiary, Ironshore Pharmaceuticals & Development, has developed a novel oral, once-daily, drug delivery technology. DELEXIS® allows drugs to be dosed at night, targeting onset of action prior to awakening.

The DELEXIS® Method of Action

Learn more about the DELEXIS® Drug Delivery Platform's micro-bead technology, and how it works to delay the absorption of drug doses.

DELEXIS® in the GI Tract

Watch the DELEXIS® micro-beads in action and see the controlled release of drugs as the beads move through a patient from ingestion to absorption.

The DELEXIS® Platform in Application

Learn how Highland and Ironshore Pharmaceuticals could use the DELEXIS® Drug-Delivery Platform to optimize dosing of existing drugs.

The Early Morning Routine

Learn about the challenges faced by families dealing with the symptoms of ADHD, and how important the early morning routine is for their quality of life.



The Before School Functioning Questionnaire (BSFQ)


The BSFQ measures both behaviors and functions associated with the post-waking, early morning period in children and adolescents with ADHD

Download the BSFQ

ADHD and the Early Morning Routine


The ADHD Market

ADHD Family Prevalence

ADHD is among the most common childhood psychiatric conditions with an estimated prevalence range of 5.9% to 7.1% in children and adolescents

ADHD US Split

In the U.S., the world’s largest ADHD market, prescription volume is split approximately equally among adults and children/adolescent patients.

Central Nervous System Stimulants

Stimulant Chart 1

Stimulant medications used at appropriate dosing levels appear more robust compared to non-stimulant treatment options.

Stimulant Chart 2

In 2014, 57.6 million stimulant medication prescriptions were written based on primary diagnosis codes of ADHD, approx. 91.5% of ADHD market volume in the U.S.

Early Morning Functioning

Time lapse before stimulant effectiveness

Current oral treatment options are dosed in the early morning, leaving the patient essentially unmedicated until drug plasma concentrations reach therapeutic levels.

Children awoken early

To address this issue, some parents wake their children up before their normal awakening time to administer their child’s medication and then let them go back to sleep.

Our Pipeline – Drug Candidates in Clinical Investigation


HLD-200

Indication: ADHD

Compound: Methylphenidate

HLD-200 at Phase III

HLD-900

Indication:
Binge Eating Disorder (BED)

Compound: Amphetamine

HLD-900 at Phase III

HLD-100

Indication: ADHD

Compound: Amphetamine

HLD-100 at Phase II

HLD-400

Indication:
Inflammatory Bowel Disease

Compound: Undisclosed

HLD-400 at Phase I

Note: These drug candidates are in clinical development and have not yet been reviewed and approved by the U.S. Food and Drug Administration.